Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Momenta Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: DewDiligence_on_SI who wrote (2530)	10/31/2010 7:18:47 PM
From: DewDiligence_on_SI	Read Replies (1) \| Respond to of 3027

MNTA ‘ReadMeFirst’ updated: siliconinvestor.com Lovenox NVS sells $292M of generic Lovenox in only 69 days; adjusting 3Q10 generic-Lovenox sales for channel stocking; how NVS accounts for Lovenox on financial statements; unspecified milestones for anniversaries of Lovenox launch; beware of SNY’s claim re Lovenox “volume”; SNY rules out an authorized generic; Teva’s version of Lovenox comes from ItalFarmaco; Teva admits its version of Lovenox not developed in-house; the sorry state of Amphastar’s application (FDA lawsuit); Lovenox knockoffs have varied potential for immunogenicity; MNTA receives (continuation) patent #7,790,466 re Lovenox characterization; OSCS still contaminates US heparin supply (good for MNTA); musings on Lovenox development outside US; new version of “What’s New in the Anticoagulant Market?” Copaxone Copaxone is cleaning clock Tysabri’s clock in US market; Tysabri now has 70 cases of PML, 20% fatal; PML info from Tysabri’s FDA label; worldwide market share in MS (pie chart); M402 M402-related paper in Journal of Hematological Oncology; M402 presentations from 2010 AACR; Miscellaneous musings on COO’s departure table of insider shareholdings.